Ocugen completes dosing in phase 2/3 trial for Stargardt disease therapy
Tweet Send to a Friend
Ocugen Inc. (NASDAQ: OCGN) announced the completion of dosing in its Phase 2/3 GARDian3 pivotal confirmatory trial for OCU410ST, a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
